Tumor-Infiltrating B Cells and Plasma Cells Influence Early-Stage Lung Cancer Biology & Immunotherapy Responses; Single-Cell Study Provides Valuable Resource to Identify New Immunotherapy Strategies; Plasma Cell Signature May Be Valuable Biomarker to Predict Immunotherapy Outcomes

Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes. The study, published on September 13, 2022 in Cancer Discovery, represents the largest and most comprehensive single-cell atlas on tumor-infiltrating B cells and plasma cells to date, which can be used to develop novel immunotherapy strategies. The open-access article is titled “The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma.”